Trial Profile
A Phase I, Randomized, Double Blind, Placebo Controlled 2-Parts Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD4205 Following Single and Multiple Ascending Dose in Healthy Adult Subjects, and to Assess the Effect of Food on the Pharmacokinetics of AZD4205
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2020
Price :
$35
*
At a glance
- Drugs Golidocitinib (Primary)
- Indications Autoimmune disorders; Inflammatory bowel diseases; Non-small cell lung cancer; Peripheral T-cell lymphoma
- Focus Adverse reactions
- Acronyms JACKPOT2
- Sponsors Dizal Pharmaceutical
- 06 Feb 2020 Status changed from active, no longer recruiting to completed.
- 28 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2020.
- 27 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.